MEDIPOST Inc. Treats First U.S. Participant in Phase III Trial of Umbilical Cord Stem Cell Therapy for Symptomatic Cartilage Defects Due to Knee Osteoarthritis
U.S. Phase III Trial Expands Clinical Investigation of Stem Cell Therapy for Knee Cartilage Defects CAMBRIDGE, Mass., July 8, 2026 /PRNewswire/ -- MEDIPOST Inc., a biotechnology company developing allogeneic, umbilical cord blood-derived stem cell...
Monport Treats Creators to Spooktacular Halloween Deals on Laser Engraving Machines
NEW YORK, Oct. 17, 2025 /PRNewswire/ -- As the Halloween season approaches, creators and small manufacturers are finding new ways to merge artistry with technology. This year, laser engraving continues to play a growing role in design,...